C57BL/6N-Atm1Brd Ifnar1tm2a(EUCOMM)Wtsi/WtsiOulu

Status

Available to order

EMMA IDEM:10181
International strain nameC57BL/6N-Atm1Brd Ifnar1tm2a(EUCOMM)Wtsi/WtsiOulu
Alternative nameMEPD01000_2_C03
Strain typeTargeted Mutant Strains
Allele/Transgene symbolIfnar1tm2a(EUCOMM)Wtsi
Gene/Transgene symbolIfnar1
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider Wellcome Trust Sanger Institute
Provider affiliationWellcome Trust Sanger Institute
Genetic informationThis mouse line originates from EUCOMM ES clone MEPD01000_2_C03. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreUniversity of Oulu, Oulu, Finland

Disease and phenotype information

IMPC phenotypes (allele matching)
  • decreased monocyte cell number / IMPC
  • abnormal vibrissa morphology / IMPC
  • improved glucose tolerance / IMPC
  • increased circulating creatinine level / IMPC
  • increased circulating amylase level / IMPC
  • decreased circulating fructosamine level / IMPC
  • increased bone mineral content / IMPC
  • decreased KLRG1-positive NK cell number / IMPC
IMPC phenotypes (gene matching)
  • improved glucose tolerance / IMPC
  • decreased circulating fructosamine level / IMPC
  • decreased monocyte cell number / IMPC
  • decreased KLRG1-positive NK cell number / IMPC
  • increased circulating creatinine level / IMPC
  • abnormal vibrissa morphology / IMPC
  • increased bone mineral content / IMPC
  • increased circulating amylase level / IMPC
MGI phenotypes (gene matching)
  • decreased bone mineral density / MGI
  • increased leukocyte cell number / MGI
  • altered susceptibility to infection / MGI
  • abnormal inflammatory response / MGI
  • increased incidence of induced tumors / MGI
  • abnormal dendritic cell physiology / MGI
  • increased susceptibility to viral infection / MGI
  • abnormal macrophage physiology / MGI
  • abnormal immunoglobulin level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • increased tumor growth/size / MGI
  • abnormal CD8-positive, alpha-beta T cell physiology / MGI
  • increased incidence of tumors by chemical induction / MGI
  • abnormal osteoclast morphology / MGI
  • abnormal response to infection / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • immune system phenotype / MGI
  • corneal vascularization / MGI
  • abnormal enzyme/coenzyme activity / MGI
  • decreased NK cell number / MGI
  • abnormal interferon-gamma secretion / MGI
  • decreased tumor necrosis factor secretion / MGI
  • decreased interferon-alpha secretion / MGI
  • decreased interferon-beta secretion / MGI
  • increased circulating interleukin-12 level / MGI
  • decreased interleukin-6 secretion / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • increased susceptibility to viral infection induced morbidity/mortality / MGI
  • abnormal NK cell physiology / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).